Monoclonal antibodies and small molecule tyrosine kinase inhibitors have a similar spectrum of cutaneous adverse reactions, with common manifestations including dryness (dry skin), pruritus, desquamation, nail/perineal changes (usually nail fungus), abnormal hair growth (usually manifested as alopecia, thick eyelashes or facial hairiness) and capillary dilation (usually manifested as swelling of small blood vessels and hyperpigmentation), while papulopustular lesions (i.e., acne or acneiform rash) are the most common cutaneous adverse reactions, occurring in 60-80% of cases. Expert advice on dose reduction or discontinuation of EGFRIs: 1. Dose reduction or discontinuation of EGFRIs must be the last option after failure of treatment for a grade III cutaneous adverse reaction, with erlotinib reduced to 100 mg/day, gefitinib to 250 mg every other day, and cetuximab to 75% of the total dose/week. Treatment should be interrupted only if the skin reaction persists for 2-4 weeks without clearing. 2. Treatment of rash cannot be stopped during discontinuation of EGFRIs. Because the rash may last for a lot of time. 3. Patients should only stop the drug temporarily and continue the drug when the rash improves. Preventive measures: 1. Ask patients to reduce the time of sun exposure and pay attention to avoiding light. The rash caused by small molecule tyrosine kinase inhibitors is mostly photosensitive and can cause a more severe rash when exposed to sunlight. 2. Keep the body clean and dry parts of the skin moist every day. Do not touch alkaline and irritating toiletries, and apply mild moisturizer or silicone cream or vitamin E ointment after bathing to prevent dry skin. 3.It is recommended to use a broad-spectrum sunscreen with SPF>18. 4.Patients with ingrown toenail (reverse peeling) may develop nail fungus and local hyperplasia reaction during the medication process. During EGFRIs treatment, it is necessary to change foot stress habits and wear loose, breathable shoes; one week before EGFRIs treatment that is hot warm water foot soak (continue in medication) or edible salt + water + white radish slices (or pepper) (boil) Applying skin care products or silicone cream after foot soak can prevent the occurrence of foot rash. Active treatment of tinea pedis. Treatment of rash, dry skin and scratching: 1. Mild toxicity: Patients may not require any form of intervention and may also use topical dermaplanin, hydrocortisone (10% or 25% ointment) or clorincosamides (10% gel), erythromycin ointment. For dry skin with itching, thin phenol glycerin lotion twice daily or benadryl ointment may be applied to the itchy area. The dose of EGFRI should not be changed due to mild toxicity. 2 weeks later, the degree of rash should be re-evaluated, and if the situation worsens or does not improve significantly, the patient will be treated for moderate toxicity. 2. Moderate toxicity: apply 2.5% hydrocortisone ointment or erythromycin ointment topically, and take Keratan orally. For dry skin with itching, apply Benadryl ointment or compound benzoic acid ointment to the itchy area 1-2 times daily. Those with spontaneous symptoms should be given oral memantine (doxycycline) 100mgBid as soon as possible, which aims to utilize the non-specific anti-inflammatory-like effect of memantine. 2 weeks later, the rash should be re-evaluated; if the situation worsens or does not improve significantly, go to the next level of treatment. 3. Severe rash: interventions are basically the same as for moderate rash, but the drug dose can be increased appropriately. If necessary, shock dose of methylprednisolone can be given and the dose of EGFRIs can be reduced; if co-infection, choose appropriate antimicrobial for treatment, such as cefuroxime 250mgbid, and consider suspending the drug or discontinuing the treatment if the adverse effects are still not sufficiently relieved after 2-4 weeks.